June 2026 in “Journal of Inflammation Research” Recent advancements in targeted therapies, such as biologics and small molecules, have transformed the treatment landscape for alopecia areata (AA), an autoimmune hair loss condition. This review discusses traditional and emerging therapies for AA, emphasizing the benefits and challenges associated with these new treatments. It also highlights the importance of real-world data collection methods and introduces GRASS-UK/GRASS-International, a global network of disease registers aimed at studying the long-term safety and effectiveness of new AA therapies.
June 2026 in “Dove Medical Press (Taylor and Francis Group)” The narrative review explores the evolving treatment landscape for alopecia areata (AA), emphasizing the role of Janus kinase (JAK) inhibitors like baricitinib, ritlecitinib, and deuruxolitinib, which have shown promise in clinical trials, such as the BRAVE-AA1 and BRAVE-AA2 trials involving about 1,200 participants. These therapies represent a shift from traditional treatments with limited efficacy. The review underscores the importance of real-world data (RWD) and disease registries, like GRASS-International, for assessing long-term safety and effectiveness. It also highlights the psychological impact of AA and the need for comprehensive care, including mental health support. Future challenges include optimizing treatment strategies, understanding long-term safety, and addressing the emotional burden on patients.
October 2025 in “Dermatologica Sinica” A personalized treatment combining traditional and new therapies may improve hair loss outcomes in alopecia areata.
47 citations
,
June 2017 in “Journal of dermatology” New treatments for alopecia areata show promise, but no cure exists and responses to treatments vary.
May 2026 in “Current Opinion in Pharmacology”